Previous 10 | Next 10 |
Total Revenue of $68 million Record Core Revenue of $67 million, growth of 48% year-over-year Raises Full Year 2023 Core Revenue Guidance to $260 million and Narrows Expected Loss Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a t...
2023-08-03 14:18:08 ET Fulgent Genetics ( NASDAQ: FLGT ) is scheduled to announce Q2 earnings results on Friday, August 4th, before market open. The consensus EPS Estimate is -$0.33 (-142.3% Y/Y) and the consensus Revenue Estimate is $62.48M (-50.2% Y/Y). Over the last...
2023-07-29 14:00:00 ET Summary Fulgent Genetics is a technology-driven company focused on clinical diagnostics and therapeutics, with recent expansion into precision medicine. FLGT's stock presents mixed signals with potential undervaluation, despite negative earnings forecasted t...
SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023. Mr. Kim currently serves as Chief Financial Off...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its second quarter 2023 financial results be...
2023-06-06 07:45:00 ET If you're looking to invest $2,500 somewhere it'll grow, but you're a bit leery of buying an increasingly overpriced and hyped-up growth stock like Nvidia , Fulgent Genetics (NASDAQ: FLGT) might be up your alley. Its shares are priced for bargain hunters, ...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced data from a Phase 1/1b clinical study of FID-007 in treating vari...
2023-05-23 09:53:00 ET Most biotechs don't have a diversified business model. They typically develop hardware, diagnostic tests, or drugs, as well as some of the associated platform technologies. But a few competitors, like 23andMe (NASDAQ: ME) and Fulgent Genetics (NASDAQ: FL...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that Phase 1/1b clinical data on its lead therapeutic development...
2023-05-14 01:47:50 ET Summary We initiate our coverage of Fulgent Genetics with an "outperform" rating and a $42 target price for the next 12 months. The company is continuing its Phase 1 clinical trial evaluating the efficacy of FID-007, a nano-encapsulated paclitaxel, in treati...
News, Short Squeeze, Breakout and More Instantly...
Fulgent Genetics Inc. Company Name:
FLGT Stock Symbol:
NASDAQ Market:
Fulgent Genetics Inc. Website:
Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, will be p...
Collaboration aims to accelerate the development of personalized therapies and transform patient care through the use of precision medicine Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: F...